Eli Lilly stock undercut its 50-day line on Jan. 14 after cutting its fourth-quarter and 2024 outlook. Is LLY stock a sell ...

A law that coaxed companies to lower the price of drugs came with a little-known consequence: smaller discounts for ...

AbbVie closed out the year on a high note, as its blockbuster biologic Skyrizi once again claimed the top spot in 2024’s ...

Digital health companies' plans focused on managing the impact of GLP-1 drugs, which have placed enormous pressure on health ...

But, no matter what direction the general market takes, some stocks could stand out, potentially in 2025, and most ...

Lilly’s decision to offer vials has also been seen as its way to combat the rise in compounding. Patients have been turning ...

Use precise geolocation data and actively scan device characteristics for identification. This is done to store and access ...

On Jan. 1, North Dakota became the first state in the country where access to drugs like Wegovy is part of the EHB package. About 55,293 of North Dakota's 784,000 residents had coverage through fully ...

Eli Lilly's dominance in the GLP-1 market and strong revenue growth forecast make LLY stock a promising investment, with a ...

With three meds approved for weight management and several on the way, these may make a dent in the obesity epidemic.

Naturally, more work is needed. Although GLS -1 agonists have been used in diabetes for 20 years, some of the newer findings ...

The best semaglutide dose for weight loss varies according to your starting weight, risks, and stage of treatment. Read to ...